Jazzhui的个人主页 - 老虎社区

Jazzhui

Jazzhui

暂无个人介绍

IP属地：未知

25关注

2粉丝

0主题

0勋章

2021-12-16

赞

@小虎综合资讯:暗盘：德商产投服务开涨2.7%，此前获1.37倍认购

2021-11-02

good app

2021-07-21

Like pls

抱歉，原内容已删除

2021-07-21

Great

Moderna stock 'has taken on a life of its own' ahead of S&P 500 entrance

2021-07-21

Nice

抱歉，原内容已删除

2021-07-21

$Apple(AAPL)$good

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4089416392578350","uuid":"4089416392578350","gmtCreate":1626313328751,"gmtModify":1635519388117,"name":"Jazzhui","pinyin":"jazzhui","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/f6cfb0e5d307c0158b75579d34f389fb","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":25,"tweetSize":6,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.12.09","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":690156010,"gmtCreate":1639648800858,"gmtModify":1639648801621,"author":{"id":"4089416392578350","authorId":"4089416392578350","name":"Jazzhui","avatar":"https://static.tigerbbs.com/f6cfb0e5d307c0158b75579d34f389fb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089416392578350","authorIdStr":"4089416392578350"},"themes":[],"htmlText":"赞","listText":"赞","text":"赞","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690156010","repostId":"690346826","repostType":1,"repost":{"id":690346826,"gmtCreate":1639642612880,"gmtModify":1639648118635,"author":{"id":"3527667586584720","authorId":"3527667586584720","name":"小虎综合资讯","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3527667586584720","authorIdStr":"3527667586584720"},"themes":[],"title":"暗盘：德商产投服务开涨2.7%，此前获1.37倍认购","htmlText":"12月16日消息，<a href=\"https://laohu8.com/S/02270\">$德商产投服务(02270)$</a>暗盘报1.14港元，较发行价涨2.7%。公司每股定价1.11港元，每手2000股，将于12月17日（周五）港股挂牌上市。 在此前的公开认购阶段，共有2517人申购德商产投服务，中签人数1981人，一手中签率70.01%，认购倍数1.37倍。老虎资讯整理相关数据如下表：分配结果 甲组每手2000股，一手中签率70.01%，申购2手稳中一手。 乙组头为1750手（350万股），获配1750手（350万股）。 所得款项净额约1.28亿港元将用作以下用途：约60%将用于进行公司战略性投资及收购，以扩大物业管理和商业运营业务；约20%将用于投资信息技术系统及支撑技术系统的人力资源；约10%将用于招募及培养人才；约10%将用作营运资金及一般公司费用。 德商产投服务是一家物业管理服务和商业运营一体化服务提供商，2020年，以在成都产生的收益计，在成都市提供物业管理服务及商业运营服务的所有公司中，公司排名第五，市场份额为0.5%。其致力于为中高端住宅物业、商业物业提供物业管理服务和商业运营服务。 于2021年5月31日，德商产投服务在管建筑面积约为4.2百万平方米，其中在管住宅物业总建筑面积约1.9百万平方米，占总管建筑面积的44.7%，在管非住宅物业总建筑面积约2.3百万平方米，占其在管建筑面积的55.3%。 公司在管建筑面积由截至2018年12月31日的约50万平方米增加至截至2020年12月31日的约380万平方米，年复合增长率约为175.7%。公司的合约建筑面积由截至2018年12月31日的约130万平方米增加至截至2020年12月31日的680万平方米，年复合增长率约为128.7%。 财务状况方面，于2018财年、2019财年、2020","listText":"12月16日消息，<a href=\"https://laohu8.com/S/02270\">$德商产投服务(02270)$</a>暗盘报1.14港元，较发行价涨2.7%。公司每股定价1.11港元，每手2000股，将于12月17日（周五）港股挂牌上市。 在此前的公开认购阶段，共有2517人申购德商产投服务，中签人数1981人，一手中签率70.01%，认购倍数1.37倍。老虎资讯整理相关数据如下表：分配结果 甲组每手2000股，一手中签率70.01%，申购2手稳中一手。 乙组头为1750手（350万股），获配1750手（350万股）。 所得款项净额约1.28亿港元将用作以下用途：约60%将用于进行公司战略性投资及收购，以扩大物业管理和商业运营业务；约20%将用于投资信息技术系统及支撑技术系统的人力资源；约10%将用于招募及培养人才；约10%将用作营运资金及一般公司费用。 德商产投服务是一家物业管理服务和商业运营一体化服务提供商，2020年，以在成都产生的收益计，在成都市提供物业管理服务及商业运营服务的所有公司中，公司排名第五，市场份额为0.5%。其致力于为中高端住宅物业、商业物业提供物业管理服务和商业运营服务。 于2021年5月31日，德商产投服务在管建筑面积约为4.2百万平方米，其中在管住宅物业总建筑面积约1.9百万平方米，占总管建筑面积的44.7%，在管非住宅物业总建筑面积约2.3百万平方米，占其在管建筑面积的55.3%。 公司在管建筑面积由截至2018年12月31日的约50万平方米增加至截至2020年12月31日的约380万平方米，年复合增长率约为175.7%。公司的合约建筑面积由截至2018年12月31日的约130万平方米增加至截至2020年12月31日的680万平方米，年复合增长率约为128.7%。 财务状况方面，于2018财年、2019财年、2020","text":"12月16日消息，$德商产投服务(02270)$暗盘报1.14港元，较发行价涨2.7%。公司每股定价1.11港元，每手2000股，将于12月17日（周五）港股挂牌上市。 在此前的公开认购阶段，共有2517人申购德商产投服务，中签人数1981人，一手中签率70.01%，认购倍数1.37倍。老虎资讯整理相关数据如下表：分配结果 甲组每手2000股，一手中签率70.01%，申购2手稳中一手。 乙组头为1750手（350万股），获配1750手（350万股）。 所得款项净额约1.28亿港元将用作以下用途：约60%将用于进行公司战略性投资及收购，以扩大物业管理和商业运营业务；约20%将用于投资信息技术系统及支撑技术系统的人力资源；约10%将用于招募及培养人才；约10%将用作营运资金及一般公司费用。 德商产投服务是一家物业管理服务和商业运营一体化服务提供商，2020年，以在成都产生的收益计，在成都市提供物业管理服务及商业运营服务的所有公司中，公司排名第五，市场份额为0.5%。其致力于为中高端住宅物业、商业物业提供物业管理服务和商业运营服务。 于2021年5月31日，德商产投服务在管建筑面积约为4.2百万平方米，其中在管住宅物业总建筑面积约1.9百万平方米，占总管建筑面积的44.7%，在管非住宅物业总建筑面积约2.3百万平方米，占其在管建筑面积的55.3%。 公司在管建筑面积由截至2018年12月31日的约50万平方米增加至截至2020年12月31日的约380万平方米，年复合增长率约为175.7%。公司的合约建筑面积由截至2018年12月31日的约130万平方米增加至截至2020年12月31日的680万平方米，年复合增长率约为128.7%。 财务状况方面，于2018财年、2019财年、2020","images":[{"img":"https://static.tigerbbs.com/16feaf9fb1e99e57db87473022c5b3aa","width":"575","height":"132"},{"img":"https://static.tigerbbs.com/86b6ab29c4d06f3d40ac7a5fd48d9ffb","width":"1059","height":"824"},{"img":"https://static.tigerbbs.com/6cab88a6528777cded10d4095c4f4c6e","width":"587","height":"658"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690346826","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":724,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":843142580,"gmtCreate":1635814988459,"gmtModify":1635814988559,"author":{"id":"4089416392578350","authorId":"4089416392578350","name":"Jazzhui","avatar":"https://static.tigerbbs.com/f6cfb0e5d307c0158b75579d34f389fb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089416392578350","authorIdStr":"4089416392578350"},"themes":[],"htmlText":"good app","listText":"good app","text":"good app","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/843142580","isVote":1,"tweetType":1,"viewCount":1849,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":178468375,"gmtCreate":1626832551297,"gmtModify":1633770575951,"author":{"id":"4089416392578350","authorId":"4089416392578350","name":"Jazzhui","avatar":"https://static.tigerbbs.com/f6cfb0e5d307c0158b75579d34f389fb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089416392578350","authorIdStr":"4089416392578350"},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/178468375","repostId":"1189562303","repostType":4,"isVote":1,"tweetType":1,"viewCount":780,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178463863,"gmtCreate":1626832470252,"gmtModify":1633770577340,"author":{"id":"4089416392578350","authorId":"4089416392578350","name":"Jazzhui","avatar":"https://static.tigerbbs.com/f6cfb0e5d307c0158b75579d34f389fb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089416392578350","authorIdStr":"4089416392578350"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/178463863","repostId":"1120529749","repostType":4,"repost":{"id":"1120529749","kind":"news","pubTimestamp":1626831113,"share":"https://www.laohu8.com/m/news/1120529749?lang=&edition=full","pubTime":"2021-07-21 09:31","market":"us","language":"en","title":"Moderna stock 'has taken on a life of its own' ahead of S&P 500 entrance","url":"https://stock-news.laohu8.com/highlight/detail?id=1120529749","media":"finance.yahoo","summary":"Moderna (MRNA) is set to join the S&P 500 index on Wednesday, replacing Alexion Pharmaceuticals Inc.","content":"<p>Moderna (MRNA) is set to join the S&amp;P 500 index on Wednesday, replacing Alexion Pharmaceuticals Inc. (ALXN). The stock hassoaredamid the pandemic after its vaccine became instrumental in the fight against coronavirus.</p>\n<p>Moderna stock has “taken on a life of its own,” Michael Yee, Managing Director and Senior Research Analyst at Jefferies, told Yahoo Finance (video above). “It's priced in a huge amount of assumptions over the next ten years that haven't played out yet. People believe it’s the Tesla of biotech.”</p>\n<p>That the biotech firm would be so well-recognized and valued at over $113 billion was no sure bet. For those who invested early in the company, that wager paid off.</p>\n<p>\"Think about how fast they came up with nothing a year ago, and all of a sudden, they're doing $21 billion and have injected hundreds and hundreds and hundreds of millions of people with their drug safely,\" Yee said. \"That's a pretty big accomplishment.\"</p>\n<p><img src=\"https://static.tigerbbs.com/bb60075c3a90de67d77af15634fd41fa\" tg-width=\"858\" tg-height=\"588\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Moderna's rise to recognition</b></p>\n<p>The Cambridge, Massachusetts-based biotech company was founded in 2010 and spent its first two years instealth modedeveloping drugs using messenger RNA (mRNA).</p>\n<p>The promise of mRNA — what Moderna calls \"the software of life\" — in pharmaceuticals has been huge. Modified mRNA teaches cells how to produce the proteins needed to fight and prevent infection. By altering the four letters in an mRNA sequence, this new class of drugs can, in theory, target a wide range of illnesses. The mRNA platform also promises to accelerate the time it takes to select, develop, and manufacture vaccines.</p>\n<p>On these high expectations, Moderna achieved a billion-dollar valuation within two years. Initially, the company focused its efforts on treatments for cancer, cardiovascular issues, and some rare diseases. However, developers were embattled with the problem of delivering mRNA to cells — too-strong doses set the body's immune system against the drug while too-weak doses proved ineffectual in fighting disease.</p>\n<p>Over time, the company shifted to pursuing vaccines, which CEO Stéphane Bancel believed would demonstrate the viability of the technology. Moderna had nine vaccines that made it to clinical trials, although none achieved liftoff.</p>\n<p>That changed when a deadly global pandemic hit, kicking off a vaccine race in the U.S. between Moderna and pharmaceutical titans like Pfizer (who also developed an mRNA vaccine in partnership with BioNTech) and Johnson &amp; Johnson.</p>\n<p>The company's decade of research iterating on the basic science behind mRNA proved consequential in its success in developing a coronavirus vaccine in record time. On January 11, 2020, Chinese scientists revealed the genetic sequence for SARS-CoV-2. By February 24, 2020, Moderna shipped thefirst dosesof its mRNA coronavirus vaccine to the NIAID to begin phase I trials. And in December of 2020, phase III trials demonstrated 94.1% efficacy against symptomatic COVID-19. The FDA subsequently approved Moderna's vaccine for emergency use in the United States, Canada, and the European Union.</p>\n<p>Moderna's COVID-19 vaccine marks its first — and only — commercially available product. On the back of strong demand for the vaccine, the company recorded its first-everprofitable quarterin Q1.</p>\n<p>The company currently has 23 othervaccines and therapeuticsin its pipeline, including vaccines for the flu, HIV, and Cytomegalovirus (CMV), which causes birth defects in newborns, all using the same mRNA technology that has seen validation from the rollout of the COVID-19 vaccine.</p>\n<p>\"I think depending on your long-term outlook of what this company could do and all of the pipeline drugs that theoretically could come about over the next 10 years, based on those prospects, it could and should be one of the largest biotech companies in the world,\" Yee said.</p>\n<p><b>A bull market in biotech</b></p>\n<p>The biotech industry has seen a phenomenal run-up in the last several years, and any pullbacks in the last six months should be viewed in that context, Yee also noted.</p>\n<p>\"It has been one of the biggest bull markets in biotech in the last three years,\" he said, citing high valuations as well as record numbers of financings, investment, and IPOs.</p>\n<p>Going forward, Yee expects more M&amp;A activity. \"Some of the large companies which are more mature, I think, are having some struggles. And the way they've solved that is often by buying smaller companies,\" he said. \"In the big picture, things have still been very good for biotech.\"</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna stock 'has taken on a life of its own' ahead of S&P 500 entrance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna stock 'has taken on a life of its own' ahead of S&P 500 entrance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-21 09:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-stock-sp-500-134049499.html><strong>finance.yahoo</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna (MRNA) is set to join the S&P 500 index on Wednesday, replacing Alexion Pharmaceuticals Inc. (ALXN). The stock hassoaredamid the pandemic after its vaccine became instrumental in the fight ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-stock-sp-500-134049499.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALXN":"亚力兄制药","MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/moderna-stock-sp-500-134049499.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1120529749","content_text":"Moderna (MRNA) is set to join the S&P 500 index on Wednesday, replacing Alexion Pharmaceuticals Inc. (ALXN). The stock hassoaredamid the pandemic after its vaccine became instrumental in the fight against coronavirus.\nModerna stock has “taken on a life of its own,” Michael Yee, Managing Director and Senior Research Analyst at Jefferies, told Yahoo Finance (video above). “It's priced in a huge amount of assumptions over the next ten years that haven't played out yet. People believe it’s the Tesla of biotech.”\nThat the biotech firm would be so well-recognized and valued at over $113 billion was no sure bet. For those who invested early in the company, that wager paid off.\n\"Think about how fast they came up with nothing a year ago, and all of a sudden, they're doing $21 billion and have injected hundreds and hundreds and hundreds of millions of people with their drug safely,\" Yee said. \"That's a pretty big accomplishment.\"\n\nModerna's rise to recognition\nThe Cambridge, Massachusetts-based biotech company was founded in 2010 and spent its first two years instealth modedeveloping drugs using messenger RNA (mRNA).\nThe promise of mRNA — what Moderna calls \"the software of life\" — in pharmaceuticals has been huge. Modified mRNA teaches cells how to produce the proteins needed to fight and prevent infection. By altering the four letters in an mRNA sequence, this new class of drugs can, in theory, target a wide range of illnesses. The mRNA platform also promises to accelerate the time it takes to select, develop, and manufacture vaccines.\nOn these high expectations, Moderna achieved a billion-dollar valuation within two years. Initially, the company focused its efforts on treatments for cancer, cardiovascular issues, and some rare diseases. However, developers were embattled with the problem of delivering mRNA to cells — too-strong doses set the body's immune system against the drug while too-weak doses proved ineffectual in fighting disease.\nOver time, the company shifted to pursuing vaccines, which CEO Stéphane Bancel believed would demonstrate the viability of the technology. Moderna had nine vaccines that made it to clinical trials, although none achieved liftoff.\nThat changed when a deadly global pandemic hit, kicking off a vaccine race in the U.S. between Moderna and pharmaceutical titans like Pfizer (who also developed an mRNA vaccine in partnership with BioNTech) and Johnson & Johnson.\nThe company's decade of research iterating on the basic science behind mRNA proved consequential in its success in developing a coronavirus vaccine in record time. On January 11, 2020, Chinese scientists revealed the genetic sequence for SARS-CoV-2. By February 24, 2020, Moderna shipped thefirst dosesof its mRNA coronavirus vaccine to the NIAID to begin phase I trials. And in December of 2020, phase III trials demonstrated 94.1% efficacy against symptomatic COVID-19. The FDA subsequently approved Moderna's vaccine for emergency use in the United States, Canada, and the European Union.\nModerna's COVID-19 vaccine marks its first — and only — commercially available product. On the back of strong demand for the vaccine, the company recorded its first-everprofitable quarterin Q1.\nThe company currently has 23 othervaccines and therapeuticsin its pipeline, including vaccines for the flu, HIV, and Cytomegalovirus (CMV), which causes birth defects in newborns, all using the same mRNA technology that has seen validation from the rollout of the COVID-19 vaccine.\n\"I think depending on your long-term outlook of what this company could do and all of the pipeline drugs that theoretically could come about over the next 10 years, based on those prospects, it could and should be one of the largest biotech companies in the world,\" Yee said.\nA bull market in biotech\nThe biotech industry has seen a phenomenal run-up in the last several years, and any pullbacks in the last six months should be viewed in that context, Yee also noted.\n\"It has been one of the biggest bull markets in biotech in the last three years,\" he said, citing high valuations as well as record numbers of financings, investment, and IPOs.\nGoing forward, Yee expects more M&A activity. \"Some of the large companies which are more mature, I think, are having some struggles. And the way they've solved that is often by buying smaller companies,\" he said. \"In the big picture, things have still been very good for biotech.\"","news_type":1,"symbols_score_info":{"ALXN":0.9,"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1534,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178485537,"gmtCreate":1626832180929,"gmtModify":1633770580928,"author":{"id":"4089416392578350","authorId":"4089416392578350","name":"Jazzhui","avatar":"https://static.tigerbbs.com/f6cfb0e5d307c0158b75579d34f389fb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089416392578350","authorIdStr":"4089416392578350"},"themes":[],"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/178485537","repostId":"1175096076","repostType":4,"isVote":1,"tweetType":1,"viewCount":757,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178482919,"gmtCreate":1626832094531,"gmtModify":1633770582053,"author":{"id":"4089416392578350","authorId":"4089416392578350","name":"Jazzhui","avatar":"https://static.tigerbbs.com/f6cfb0e5d307c0158b75579d34f389fb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089416392578350","authorIdStr":"4089416392578350"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>good","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>good","text":"$Apple(AAPL)$good","images":[{"img":"https://static.tigerbbs.com/fe1a2c0924bddce896443cbd13677276","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/178482919","isVote":1,"tweetType":1,"viewCount":1058,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":178485537,"gmtCreate":1626832180929,"gmtModify":1633770580928,"author":{"id":"4089416392578350","authorId":"4089416392578350","name":"Jazzhui","avatar":"https://static.tigerbbs.com/f6cfb0e5d307c0158b75579d34f389fb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089416392578350","authorIdStr":"4089416392578350"},"themes":[],"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/178485537","repostId":"1175096076","repostType":4,"isVote":1,"tweetType":1,"viewCount":757,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178468375,"gmtCreate":1626832551297,"gmtModify":1633770575951,"author":{"id":"4089416392578350","authorId":"4089416392578350","name":"Jazzhui","avatar":"https://static.tigerbbs.com/f6cfb0e5d307c0158b75579d34f389fb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089416392578350","authorIdStr":"4089416392578350"},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/178468375","repostId":"1189562303","repostType":4,"isVote":1,"tweetType":1,"viewCount":780,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178463863,"gmtCreate":1626832470252,"gmtModify":1633770577340,"author":{"id":"4089416392578350","authorId":"4089416392578350","name":"Jazzhui","avatar":"https://static.tigerbbs.com/f6cfb0e5d307c0158b75579d34f389fb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089416392578350","authorIdStr":"4089416392578350"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/178463863","repostId":"1120529749","repostType":4,"repost":{"id":"1120529749","kind":"news","pubTimestamp":1626831113,"share":"https://www.laohu8.com/m/news/1120529749?lang=&edition=full","pubTime":"2021-07-21 09:31","market":"us","language":"en","title":"Moderna stock 'has taken on a life of its own' ahead of S&P 500 entrance","url":"https://stock-news.laohu8.com/highlight/detail?id=1120529749","media":"finance.yahoo","summary":"Moderna (MRNA) is set to join the S&P 500 index on Wednesday, replacing Alexion Pharmaceuticals Inc.","content":"<p>Moderna (MRNA) is set to join the S&amp;P 500 index on Wednesday, replacing Alexion Pharmaceuticals Inc. (ALXN). The stock hassoaredamid the pandemic after its vaccine became instrumental in the fight against coronavirus.</p>\n<p>Moderna stock has “taken on a life of its own,” Michael Yee, Managing Director and Senior Research Analyst at Jefferies, told Yahoo Finance (video above). “It's priced in a huge amount of assumptions over the next ten years that haven't played out yet. People believe it’s the Tesla of biotech.”</p>\n<p>That the biotech firm would be so well-recognized and valued at over $113 billion was no sure bet. For those who invested early in the company, that wager paid off.</p>\n<p>\"Think about how fast they came up with nothing a year ago, and all of a sudden, they're doing $21 billion and have injected hundreds and hundreds and hundreds of millions of people with their drug safely,\" Yee said. \"That's a pretty big accomplishment.\"</p>\n<p><img src=\"https://static.tigerbbs.com/bb60075c3a90de67d77af15634fd41fa\" tg-width=\"858\" tg-height=\"588\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Moderna's rise to recognition</b></p>\n<p>The Cambridge, Massachusetts-based biotech company was founded in 2010 and spent its first two years instealth modedeveloping drugs using messenger RNA (mRNA).</p>\n<p>The promise of mRNA — what Moderna calls \"the software of life\" — in pharmaceuticals has been huge. Modified mRNA teaches cells how to produce the proteins needed to fight and prevent infection. By altering the four letters in an mRNA sequence, this new class of drugs can, in theory, target a wide range of illnesses. The mRNA platform also promises to accelerate the time it takes to select, develop, and manufacture vaccines.</p>\n<p>On these high expectations, Moderna achieved a billion-dollar valuation within two years. Initially, the company focused its efforts on treatments for cancer, cardiovascular issues, and some rare diseases. However, developers were embattled with the problem of delivering mRNA to cells — too-strong doses set the body's immune system against the drug while too-weak doses proved ineffectual in fighting disease.</p>\n<p>Over time, the company shifted to pursuing vaccines, which CEO Stéphane Bancel believed would demonstrate the viability of the technology. Moderna had nine vaccines that made it to clinical trials, although none achieved liftoff.</p>\n<p>That changed when a deadly global pandemic hit, kicking off a vaccine race in the U.S. between Moderna and pharmaceutical titans like Pfizer (who also developed an mRNA vaccine in partnership with BioNTech) and Johnson &amp; Johnson.</p>\n<p>The company's decade of research iterating on the basic science behind mRNA proved consequential in its success in developing a coronavirus vaccine in record time. On January 11, 2020, Chinese scientists revealed the genetic sequence for SARS-CoV-2. By February 24, 2020, Moderna shipped thefirst dosesof its mRNA coronavirus vaccine to the NIAID to begin phase I trials. And in December of 2020, phase III trials demonstrated 94.1% efficacy against symptomatic COVID-19. The FDA subsequently approved Moderna's vaccine for emergency use in the United States, Canada, and the European Union.</p>\n<p>Moderna's COVID-19 vaccine marks its first — and only — commercially available product. On the back of strong demand for the vaccine, the company recorded its first-everprofitable quarterin Q1.</p>\n<p>The company currently has 23 othervaccines and therapeuticsin its pipeline, including vaccines for the flu, HIV, and Cytomegalovirus (CMV), which causes birth defects in newborns, all using the same mRNA technology that has seen validation from the rollout of the COVID-19 vaccine.</p>\n<p>\"I think depending on your long-term outlook of what this company could do and all of the pipeline drugs that theoretically could come about over the next 10 years, based on those prospects, it could and should be one of the largest biotech companies in the world,\" Yee said.</p>\n<p><b>A bull market in biotech</b></p>\n<p>The biotech industry has seen a phenomenal run-up in the last several years, and any pullbacks in the last six months should be viewed in that context, Yee also noted.</p>\n<p>\"It has been one of the biggest bull markets in biotech in the last three years,\" he said, citing high valuations as well as record numbers of financings, investment, and IPOs.</p>\n<p>Going forward, Yee expects more M&amp;A activity. \"Some of the large companies which are more mature, I think, are having some struggles. And the way they've solved that is often by buying smaller companies,\" he said. \"In the big picture, things have still been very good for biotech.\"</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna stock 'has taken on a life of its own' ahead of S&P 500 entrance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna stock 'has taken on a life of its own' ahead of S&P 500 entrance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-21 09:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-stock-sp-500-134049499.html><strong>finance.yahoo</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna (MRNA) is set to join the S&P 500 index on Wednesday, replacing Alexion Pharmaceuticals Inc. (ALXN). The stock hassoaredamid the pandemic after its vaccine became instrumental in the fight ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-stock-sp-500-134049499.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALXN":"亚力兄制药","MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/moderna-stock-sp-500-134049499.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1120529749","content_text":"Moderna (MRNA) is set to join the S&P 500 index on Wednesday, replacing Alexion Pharmaceuticals Inc. (ALXN). The stock hassoaredamid the pandemic after its vaccine became instrumental in the fight against coronavirus.\nModerna stock has “taken on a life of its own,” Michael Yee, Managing Director and Senior Research Analyst at Jefferies, told Yahoo Finance (video above). “It's priced in a huge amount of assumptions over the next ten years that haven't played out yet. People believe it’s the Tesla of biotech.”\nThat the biotech firm would be so well-recognized and valued at over $113 billion was no sure bet. For those who invested early in the company, that wager paid off.\n\"Think about how fast they came up with nothing a year ago, and all of a sudden, they're doing $21 billion and have injected hundreds and hundreds and hundreds of millions of people with their drug safely,\" Yee said. \"That's a pretty big accomplishment.\"\n\nModerna's rise to recognition\nThe Cambridge, Massachusetts-based biotech company was founded in 2010 and spent its first two years instealth modedeveloping drugs using messenger RNA (mRNA).\nThe promise of mRNA — what Moderna calls \"the software of life\" — in pharmaceuticals has been huge. Modified mRNA teaches cells how to produce the proteins needed to fight and prevent infection. By altering the four letters in an mRNA sequence, this new class of drugs can, in theory, target a wide range of illnesses. The mRNA platform also promises to accelerate the time it takes to select, develop, and manufacture vaccines.\nOn these high expectations, Moderna achieved a billion-dollar valuation within two years. Initially, the company focused its efforts on treatments for cancer, cardiovascular issues, and some rare diseases. However, developers were embattled with the problem of delivering mRNA to cells — too-strong doses set the body's immune system against the drug while too-weak doses proved ineffectual in fighting disease.\nOver time, the company shifted to pursuing vaccines, which CEO Stéphane Bancel believed would demonstrate the viability of the technology. Moderna had nine vaccines that made it to clinical trials, although none achieved liftoff.\nThat changed when a deadly global pandemic hit, kicking off a vaccine race in the U.S. between Moderna and pharmaceutical titans like Pfizer (who also developed an mRNA vaccine in partnership with BioNTech) and Johnson & Johnson.\nThe company's decade of research iterating on the basic science behind mRNA proved consequential in its success in developing a coronavirus vaccine in record time. On January 11, 2020, Chinese scientists revealed the genetic sequence for SARS-CoV-2. By February 24, 2020, Moderna shipped thefirst dosesof its mRNA coronavirus vaccine to the NIAID to begin phase I trials. And in December of 2020, phase III trials demonstrated 94.1% efficacy against symptomatic COVID-19. The FDA subsequently approved Moderna's vaccine for emergency use in the United States, Canada, and the European Union.\nModerna's COVID-19 vaccine marks its first — and only — commercially available product. On the back of strong demand for the vaccine, the company recorded its first-everprofitable quarterin Q1.\nThe company currently has 23 othervaccines and therapeuticsin its pipeline, including vaccines for the flu, HIV, and Cytomegalovirus (CMV), which causes birth defects in newborns, all using the same mRNA technology that has seen validation from the rollout of the COVID-19 vaccine.\n\"I think depending on your long-term outlook of what this company could do and all of the pipeline drugs that theoretically could come about over the next 10 years, based on those prospects, it could and should be one of the largest biotech companies in the world,\" Yee said.\nA bull market in biotech\nThe biotech industry has seen a phenomenal run-up in the last several years, and any pullbacks in the last six months should be viewed in that context, Yee also noted.\n\"It has been one of the biggest bull markets in biotech in the last three years,\" he said, citing high valuations as well as record numbers of financings, investment, and IPOs.\nGoing forward, Yee expects more M&A activity. \"Some of the large companies which are more mature, I think, are having some struggles. And the way they've solved that is often by buying smaller companies,\" he said. \"In the big picture, things have still been very good for biotech.\"","news_type":1,"symbols_score_info":{"ALXN":0.9,"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1534,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178482919,"gmtCreate":1626832094531,"gmtModify":1633770582053,"author":{"id":"4089416392578350","authorId":"4089416392578350","name":"Jazzhui","avatar":"https://static.tigerbbs.com/f6cfb0e5d307c0158b75579d34f389fb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089416392578350","authorIdStr":"4089416392578350"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>good","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>good","text":"$Apple(AAPL)$good","images":[{"img":"https://static.tigerbbs.com/fe1a2c0924bddce896443cbd13677276","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/178482919","isVote":1,"tweetType":1,"viewCount":1058,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":690156010,"gmtCreate":1639648800858,"gmtModify":1639648801621,"author":{"id":"4089416392578350","authorId":"4089416392578350","name":"Jazzhui","avatar":"https://static.tigerbbs.com/f6cfb0e5d307c0158b75579d34f389fb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089416392578350","authorIdStr":"4089416392578350"},"themes":[],"htmlText":"赞","listText":"赞","text":"赞","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690156010","repostId":"690346826","repostType":1,"repost":{"id":690346826,"gmtCreate":1639642612880,"gmtModify":1639648118635,"author":{"id":"3527667586584720","authorId":"3527667586584720","name":"小虎综合资讯","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3527667586584720","authorIdStr":"3527667586584720"},"themes":[],"title":"暗盘：德商产投服务开涨2.7%，此前获1.37倍认购","htmlText":"12月16日消息，<a href=\"https://laohu8.com/S/02270\">$德商产投服务(02270)$</a>暗盘报1.14港元，较发行价涨2.7%。公司每股定价1.11港元，每手2000股，将于12月17日（周五）港股挂牌上市。 在此前的公开认购阶段，共有2517人申购德商产投服务，中签人数1981人，一手中签率70.01%，认购倍数1.37倍。老虎资讯整理相关数据如下表：分配结果 甲组每手2000股，一手中签率70.01%，申购2手稳中一手。 乙组头为1750手（350万股），获配1750手（350万股）。 所得款项净额约1.28亿港元将用作以下用途：约60%将用于进行公司战略性投资及收购，以扩大物业管理和商业运营业务；约20%将用于投资信息技术系统及支撑技术系统的人力资源；约10%将用于招募及培养人才；约10%将用作营运资金及一般公司费用。 德商产投服务是一家物业管理服务和商业运营一体化服务提供商，2020年，以在成都产生的收益计，在成都市提供物业管理服务及商业运营服务的所有公司中，公司排名第五，市场份额为0.5%。其致力于为中高端住宅物业、商业物业提供物业管理服务和商业运营服务。 于2021年5月31日，德商产投服务在管建筑面积约为4.2百万平方米，其中在管住宅物业总建筑面积约1.9百万平方米，占总管建筑面积的44.7%，在管非住宅物业总建筑面积约2.3百万平方米，占其在管建筑面积的55.3%。 公司在管建筑面积由截至2018年12月31日的约50万平方米增加至截至2020年12月31日的约380万平方米，年复合增长率约为175.7%。公司的合约建筑面积由截至2018年12月31日的约130万平方米增加至截至2020年12月31日的680万平方米，年复合增长率约为128.7%。 财务状况方面，于2018财年、2019财年、2020","listText":"12月16日消息，<a href=\"https://laohu8.com/S/02270\">$德商产投服务(02270)$</a>暗盘报1.14港元，较发行价涨2.7%。公司每股定价1.11港元，每手2000股，将于12月17日（周五）港股挂牌上市。 在此前的公开认购阶段，共有2517人申购德商产投服务，中签人数1981人，一手中签率70.01%，认购倍数1.37倍。老虎资讯整理相关数据如下表：分配结果 甲组每手2000股，一手中签率70.01%，申购2手稳中一手。 乙组头为1750手（350万股），获配1750手（350万股）。 所得款项净额约1.28亿港元将用作以下用途：约60%将用于进行公司战略性投资及收购，以扩大物业管理和商业运营业务；约20%将用于投资信息技术系统及支撑技术系统的人力资源；约10%将用于招募及培养人才；约10%将用作营运资金及一般公司费用。 德商产投服务是一家物业管理服务和商业运营一体化服务提供商，2020年，以在成都产生的收益计，在成都市提供物业管理服务及商业运营服务的所有公司中，公司排名第五，市场份额为0.5%。其致力于为中高端住宅物业、商业物业提供物业管理服务和商业运营服务。 于2021年5月31日，德商产投服务在管建筑面积约为4.2百万平方米，其中在管住宅物业总建筑面积约1.9百万平方米，占总管建筑面积的44.7%，在管非住宅物业总建筑面积约2.3百万平方米，占其在管建筑面积的55.3%。 公司在管建筑面积由截至2018年12月31日的约50万平方米增加至截至2020年12月31日的约380万平方米，年复合增长率约为175.7%。公司的合约建筑面积由截至2018年12月31日的约130万平方米增加至截至2020年12月31日的680万平方米，年复合增长率约为128.7%。 财务状况方面，于2018财年、2019财年、2020","text":"12月16日消息，$德商产投服务(02270)$暗盘报1.14港元，较发行价涨2.7%。公司每股定价1.11港元，每手2000股，将于12月17日（周五）港股挂牌上市。 在此前的公开认购阶段，共有2517人申购德商产投服务，中签人数1981人，一手中签率70.01%，认购倍数1.37倍。老虎资讯整理相关数据如下表：分配结果 甲组每手2000股，一手中签率70.01%，申购2手稳中一手。 乙组头为1750手（350万股），获配1750手（350万股）。 所得款项净额约1.28亿港元将用作以下用途：约60%将用于进行公司战略性投资及收购，以扩大物业管理和商业运营业务；约20%将用于投资信息技术系统及支撑技术系统的人力资源；约10%将用于招募及培养人才；约10%将用作营运资金及一般公司费用。 德商产投服务是一家物业管理服务和商业运营一体化服务提供商，2020年，以在成都产生的收益计，在成都市提供物业管理服务及商业运营服务的所有公司中，公司排名第五，市场份额为0.5%。其致力于为中高端住宅物业、商业物业提供物业管理服务和商业运营服务。 于2021年5月31日，德商产投服务在管建筑面积约为4.2百万平方米，其中在管住宅物业总建筑面积约1.9百万平方米，占总管建筑面积的44.7%，在管非住宅物业总建筑面积约2.3百万平方米，占其在管建筑面积的55.3%。 公司在管建筑面积由截至2018年12月31日的约50万平方米增加至截至2020年12月31日的约380万平方米，年复合增长率约为175.7%。公司的合约建筑面积由截至2018年12月31日的约130万平方米增加至截至2020年12月31日的680万平方米，年复合增长率约为128.7%。 财务状况方面，于2018财年、2019财年、2020","images":[{"img":"https://static.tigerbbs.com/16feaf9fb1e99e57db87473022c5b3aa","width":"575","height":"132"},{"img":"https://static.tigerbbs.com/86b6ab29c4d06f3d40ac7a5fd48d9ffb","width":"1059","height":"824"},{"img":"https://static.tigerbbs.com/6cab88a6528777cded10d4095c4f4c6e","width":"587","height":"658"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690346826","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":724,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":843142580,"gmtCreate":1635814988459,"gmtModify":1635814988559,"author":{"id":"4089416392578350","authorId":"4089416392578350","name":"Jazzhui","avatar":"https://static.tigerbbs.com/f6cfb0e5d307c0158b75579d34f389fb","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089416392578350","authorIdStr":"4089416392578350"},"themes":[],"htmlText":"good app","listText":"good app","text":"good app","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/843142580","isVote":1,"tweetType":1,"viewCount":1849,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}